Abstracts Archive - Page 1443 of 2425 - ACR Meeting Abstracts

Abstract Number: 376 • 2016 ACR/ARHP Annual Meeting
Initial Validation of the Patient Reported Outcomes Measurement Information System Pediatric Pain Intensity Scale in Juvenile Idiopathic Arthritis, Juvenile Fibromyalgia and Sickle Cell Disease
Esi Morgan¹, Constance Mara², Bin Huang³, Adam Carle⁴, Kenneth Goldschneider⁵, Carlton Dampier⁶ and Susmita Kashikar-Zuck⁷, ¹Pediatric Rheumatology, Cincinnati Children's Hospital, Cincinnati, OH, ²James M. Anderson Center for Health Systems Excellence, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ³Biostatistics and Epidemiology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ⁴Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ⁵Anesthesia, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ⁶Department of Pediatrics (Hematology-Oncology), Emory University School of Medicine, Atlanta, GA, ⁷Behavioral Medicine & Clinical Psychology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH
Background/Purpose: The Patient Reported Outcomes Measurement Information System(PROMIS) is a publicly available assessment system offering multiple measures to assess physical, mental and social health.…
Abstract Number: 377 • 2016 ACR/ARHP Annual Meeting
Pain and Quality of Life Profiles in Colombian Patients with Rheumatoid Arthritis: A Mixed Cluster Analysis
Juan Manuel Cotte¹, Nicolás Molano-González², Deisy Hernández-Parra³, Yenifer Delgado-Scarpetta³, Adriana Rojas-Villarraga², Juan-Manuel Anaya¹ and Ricardo Pineda-Tamayo³, ¹Center for Autoimmune Diseases Research (CREA). School of Medicine and Health Sciences, Universidad del Rosario, Bogotá, Colombia., Bogotá, Colombia, ²Center for Autoimmune Diseases Research (CREA). School of Medicine and Health Sciences, Universidad del Rosario, Bogotá, Colombia., Bogotá D.C., Colombia, ³Artmédica IPS, Medellin, Colombia, Medellin, Colombia
ABSTRACT Background/Purpose: Among the symptoms of Rheumatoid Arthritis (RA), pain is often regarded as a critical factor related to quality of life (QoL) by patients,…
Abstract Number: 378 • 2016 ACR/ARHP Annual Meeting
Effects of a Natural Product Containing Specialized Pro-Resolving Mediators in Subjects with OA, RA, or Other Chronic Inflammatory Conditions in a Multi-Clinic Case Series
Annalouise O'Connor¹, Sara Le Brun-Blashka², Kirti Salunkhe², Jyh-Lurn Chang² and John Troup², ¹R&D, Metagenics, Inc., Gig Harbor, WA, ²Metagenics, Inc., Gig Harbor, WA
Background/Purpose: The inflammatory response has an initiation phase and a resolution phase. Ideally, inflammation leads to complete resolution that enables tissue healing and a return…
Abstract Number: 379 • 2016 ACR/ARHP Annual Meeting
Pain Catastrophizing Decreases in RA Patients Starting, Adding or Switching a DMARD
Ezra Cohen¹, Alyssa Wohlfahrt², Robert R. Edwards³, Clifton Bingham III⁴, Marcy Bolster⁵, Larry W. Moreland⁶, Tuhina Neogi⁷, Kristine Phillips⁸ and Yvonne C. Lee⁹, ¹Boston Children's Hospital, Boston, MA, ²Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA, ³Anesthesiology, Brigham & Womens Hospital, Chestnut Hill, MA, ⁴Divisions of Rheumatology and Allergy, Department of Medicine, Johns Hopkins University, Johns Hopkins University, Baltimore, MD, ⁵Rheumatology, Allergy and Immunology, Massachusetts General Hospital, Boston, MA, ⁶Rheumatology & Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, ⁷Clinical Epidemiology, Boston University School of Medicine, Boston, MA, ⁸Rheumatology, University of Michigan, Ann Arbor, MI, ⁹Rheumatology Immunology & Allergy, Brigham and Women's Hospital and Harvard Medical School, Boston, MA
Background/Purpose: In individuals with RA, catastrophizing is associated with poor pain outcomes. It is not known whether catastrophizing can be altered by treating RA…
Abstract Number: 380 • 2016 ACR/ARHP Annual Meeting
Linear Discriminant Analysis of Cultured Fibroblast-like Synoviocytes Identifies 6 Candidate Genes Which Predict Extended Course in Juvenile Idiopathic Arthritis
AnneMarie Brescia¹, Megan Simonds², Suzanne McCahan³, Tim Bunnell³, Kathleen E. Sullivan⁴ and Carlos D. Rosé¹, ¹Pediatric Rheumatology, Thomas Jefferson University/ AI duPont Hospital for Children, Wilmington, DE, ²Nemours, Nemours Biomedical Research, Wilmington, DE, ³Nemours Biomedical Research, Wilmington, DE, ⁴Allergy Immunology, The Children's Hospital of Philadelphia, Philadelphia, PA
Background/Purpose: The goal of this project is the identification of informative synovial biomarkers to predict which children with oligoarticular juvenile idiopathic arthritis (JIA) will have…
Abstract Number: 381 • 2016 ACR/ARHP Annual Meeting
Calprotectin As a Multipotent Biomarker in Juvenile Idiopathic Arthritis
Celine La¹, Phu-Quoc Le², Bernard R. Lauwerys³, Laurence Goffin⁴, Alina Ferster⁵, Julie Smet⁶, Patrick Stordeur⁷, Cecile Boulanger⁸, Jean-Pierre Brasseur⁹, Benoit Brasseur¹⁰, David Tuerlincks¹¹, Delphine Spruyt¹², Paschalis Sidiras¹³, Joanne Rasschaert¹², Viviane de Maertelaer¹⁴, Sandra Kleimberg¹⁵, Tatiana Sokolova¹⁶, Patrick Durez^17,18 and Valérie Badot^1,19, ¹Rheumatology, Hôpital Erasme,Université Libre de Bruxelles, Brussels, Belgium, ²Service d'hemato-oncologie, Hopital Universitaire des enfants Reine Fabiola (HUDERF), 1020, Belgium, ³Service de rhumatologie, Pôle de pathologies rhumatismales inflammatoires et systémiques, Cliniques Universitaires Saint-Luc, Université Catholique de Louvain, Brussels, Belgium, ⁴Service de pédiatrie, Hopital Universitaire des enfants Reine Fabiola (HUDERF), Brussels, Belgium, ⁵Service d'Onco-Hématologie, Hôpital Reine Fabiola, Brussels, Belgium, ⁶Laboratorire d'Immunologie, Hopital Erasme-Université Libre de Bruxelles, Brussels, Belgium, ⁷Laboratoire d'Immunologie, Hopital Erasme-Université Libre de Bruxelles, Brussels, Belgium, ⁸Service d'hématologie et Oncologie pédiatrique, Clinique universitaire Saint-Luc, Brussels, Belgium, ⁹Service de rhumatologie, Hopital Universitaire Mont-Godinne, Yvoir, Belgium, ¹⁰Service de Pédiatrie, Hopital Universitaire Mont-Godinne, Yvoir, Belgium, ¹¹Service de pédiatrie, Hopital Universitaire Mont-Godinne, Yvoir, Belgium, ¹²Laboratory of Bone and Metabolic Biochemistry, Université Libre de Bruxelles, Brussels, Belgium, ¹³Service de Rhumatologie, Hopital Erasme-Université Libre de Bruxelles, Brussels, Belgium, ¹⁴Service de Biostatistique et Informatique Médicale, Université Libre de Bruxelles, Brussels, Belgium, ¹⁵Service de Rhumatologie et de Médecine Physique, Hopital Erasme-Université Libre de Bruxelles, Brussels, Belgium, ¹⁶Project Coordinator, CAP 48 cohort, Brussels, Belgium, ¹⁷Service de Rhumatologie, Cliniques Universitaires Saint-Luc, Brussels, Belgium, ¹⁸Pôle de pathologies rhumatismales inflammatoires et systémiques, Institut de Recherche Expérimentale et Clinique, Université catholique de Louvain, Brussels, Belgium, ¹⁹Department of Rheumatology, Hôpital Erasme, Université Libre de Bruxelles, Brussels, Belgium
Background/Purpose: Lack of specific diagnostic, prognostic or response to treatment markers in juvenile idiopathic arthritis (JIA) leads to study new potential markers, as serum calprotectin…
Abstract Number: 382 • 2016 ACR/ARHP Annual Meeting
Tumor Necrosis Factor-α -308 a/G Gene Polymorphism in Children with Juvenile Idiopathic Arthritis: Relation to Disease Activity, Damage and Disability
Tamer Gheita¹, Iman El Gazzar², Hanan Fathy³, Abeer Nour El-Din⁴, Enas Abdel Rasheed⁵, Rasha Bassyouni⁶ and Sanaa Kenawy⁷, ¹Rheumatology, Rheumatology Department, Faculty of Medicine, Cairo University, Egypt, Cairo, Egypt, ²Rheumatology, Rheumatology Department, Faculty of Medicine, Cairo University, Cairo, Egypt, ³Rheumatology, Rheumatology Department, Faculty of Medicine, Fayoum University, Fayoum, Egypt, ⁴Pediatric Department, National Research Centre, Dokki, Egypt, Giza, Egypt, ⁵Clinical Pathology Department, National Research Centre, Dokki, Egypt, Giza, Egypt, ⁶Medical Microbiology and Immunology Department, Faculty of Medicine, Fayoum University, Fayoum, Egypt, ⁷Pharmacology, Pharmacology Department, Faculty of Pharmacy, Cairo University, Cairo, Egypt
Background/Purpose: Juvenile idiopathic arthritis (JIA) is the most common chronic rheumatic disease of childhood and an important cause of disability. Its cause remains unknown, but…
Abstract Number: 383 • 2016 ACR/ARHP Annual Meeting
Potential Biomarkers of Disease Activity in Juvenile Idiopathic Arthritis – Data from the Portuguese Register, Reuma.Pt
Ana Filipa Mourão^1,2,3, MJ Santos⁴, Mónica Eusébio⁵, Ana Lopes⁶, Filipa Ramos⁷, Manuel Salgado⁸, Paula Estanqueiro⁹, Jose Antonio Melo Gomes¹⁰, Fernando Magalhaes Martins¹¹, José Antonio Costa¹², Ana Carolina Furtado¹³, Ricardo Figueira¹⁴, Iva Brito^15,16,17, Jaime Branco^18,19, João E. Fonseca²⁰ and Helena Canhão²¹, ¹NOVA Medical School - Faculdade Ciências Médicas da Universidade Nova de Lisboa, Lisbon, Portugal, ²Centro Hospitalar Lisboa Ocidental (CHLO- E.P.E.), Lisbon, Portugal, ³Rheumatology, Instituto de Medicina Molecular, Lisbon, Portugal, ⁴Rheumatology Research Unit Instituto de Medicina Molecular, Faculty of Medicine, University of Lisbon, Lisbon, Portugal, ⁵Sociedade Portuguesa de Reumatologia, LIsboa, Portugal, ⁶Rheumatology Research Unit, Instituto de Medicina Molecular, Faculdade de Medicina da Universidade de Lisboa, Lisbon, Portugal, ⁷Rheumatology and Metabolic Bone Diseases Department, Santa Maria Hospital,CHLN, Lisbon, Portugal, ⁸Pediatrics, Centro Hospitalar de Coimbra, Coimbra, Portugal, ⁹Pediatrics, Centro Hospitalar da Universidade de Coimbra, Coimbra, Portugal, ¹⁰Instituto Português de Reumatologia, Lisbon, Portugal, ¹¹Portuguese Society of Rheumatology, Lisbon, Portugal, ¹²Rheumatology, Centro Hospitalar do Alto Minho, Hospital de Ponte de Lima, Ponte de Lima, Portugal, ¹³Rheumatology, Hospital do Divino Espírito Santo, Ponta Delgada, São Miguel, Portugal, ¹⁴Rheumatology, Hospital Dr. Nélio Mendonça, Funchal, Portugal, ¹⁵Rheumatology, Centro Hospitalar do Pirto, Hospital de São João, Porto, Portugal, ¹⁶Rua Raul Caldevilla 126-2 Dto, Hospital Sao Joao, Porto, Portugal, ¹⁷Faculdade de Medicina da Universidade do Porto, Porto, Portugal, ¹⁸Rheumatology, CHLO, Hospital Egas Moniz, Lisbon, Portugal, ¹⁹CEDOC, Nova Medical School, Lisbon, Portugal, ²⁰Rheumatology Research Unit, Instituto de Medicina Molecular, Faculdade de Medicina, Universidade de Lisboa, Lisbon, Portugal, Lisboa, Portugal, ²¹Rheumatology Research Unit, Instituto de Medicina Molecular, Lisbon, Portugal
, IL6, IL10, IL17 and TNF in patients with JIA, and detect their relation to disease activity. Results: 281 patients, 66% female, mean age 17.3±10…
Abstract Number: 384 • 2016 ACR/ARHP Annual Meeting
WITHDRAWN
Abstract Number: 385 • 2016 ACR/ARHP Annual Meeting
Safety of Adalimumab in Pediatric Patients with Polyarticular Juvenile Idiopathic Arthritis, Enthesitis-Related Arthritis, Psoriasis, and Crohn’s Disease
Gerd Horneff¹, Marieke M. B. Seyger², Dilek Arikan³, Jasmina Kalabic⁴, Jaclyn K. Anderson³, Andreas Lazar⁵, David A. Williams³, Chen Wang³, Rita Tarzynski-Potempa³ and Jeffrey S. Hyams⁶, ¹Asklepios Kliniken GmbH, Hamburg, Germany, ²Radboud University Nijmegen Medical Center, Nijmegen, Netherlands, ³AbbVie Inc., North Chicago, IL, ⁴AbbVie Deutschland GmbH & Co. KG, Ludwigshafen, Germany, ⁵AbbVie Deutschland GmbH & Co. KG, North ChicagoLudwigshafen, IL, Germany, ⁶Connecticut Children’s Medical Center, Hartford, CT
Background/Purpose: Adalimumab (ADA) is a tumor necrosis factor (TNF) inhibitor used for treatment of chronic immune diseases. The safety of ADA treatment in pediatric patients…
Abstract Number: 386 • 2016 ACR/ARHP Annual Meeting
Long-Term Efficacy and Safety of Adalimumab in Pediatric Patients with Enthesitis Related Arthritis
Rubén Burgos-Vargas¹, Shirley M.L. Tse², Gerd Horneff³, Kristina Unnebrink⁴ and Jaclyn K. Anderson⁵, ¹Hospital General de Mexico, Universidad Nacional Autonoma de Mexico, Mexico City, Mexico, ²University of Toronto, The Hospital for Sick Children, Toronto, ON, Canada, ³Asklepios Clinc Sankt Augustin, Sankt Augustin, Germany, ⁴AbbVie Deutschland GmbH & Co. KG, Ludwigshafen, Germany, ⁵AbbVie Inc., North Chicago, IL
Background/Purpose: Enthesitis-related arthritis (ERA) is a JIA category primarily affecting entheses and peripheral joints but can involve the axial skeleton. Disease activity and structural change…
Abstract Number: 387 • 2016 ACR/ARHP Annual Meeting
Rituximab Should be Considered in Rheumatoid Factor Negative Poly-Articular Juvenile Idiopathic Arthritis
Sunil Sampath^1,2, Liza J. McCann³, Michael W. Beresford^3,4, Eileen Baildam³, Jamie C Sergeant^1,5, Wendy Thomson², Helen Foster⁶, Sharon Douglas², Taunton Southwood⁷, Kimme L. Hyrich¹ and Biologics for Children with Rheumatic Diseases (BCRD) study Group¹, ¹Arthritis Research UK Centre for Epidemiology, The University of Manchester, Manchester, United Kingdom, ²Arthritis Research UK Centre for Genetics and Genomics,The University of Manchester, Manchester, United Kingdom, ³Paediatric Rheumatology, Alder Hey Children's NHS Foundation Trust, Liverpool, United Kingdom, ⁴Alder Hey Children's NHS Foundation Trust Hospital, Institute of Translational Medicine (Child Health), University of Liverpool, Liverpool, United Kingdom, ⁵NIHR Manchester Musculoskeletal Biomedical Research Unit, Central Manchester University Hospitals NHS Foundation Trust, Manchester, United Kingdom, ⁶Paediatric Rheumatology, Musculoskeletal Research Group, Institute of Cellular Medicine, Newcastle University and Great North Children's Hospital, Newcastle Upon Tyne, United Kingdom, ⁷School of Immunity and Infection,Institute of Clinical Sciences,University of Birmingham, Birmingham, United Kingdom
Background/Purpose: Selective peripheral B-cell depletion by rituximab (RTX) is a relatively recent advance in rheumatic diseases. RTX is an approved treatment in RA. Although very…
Abstract Number: 388 • 2016 ACR/ARHP Annual Meeting
Pharmacokinetics, Safety, and Tolerability of Tofacitinib in Pediatric Patients from Two to Less Than Eighteen Years of Age with Juvenile Idiopathic Arthritis
Hermine I. Brunner¹, Nicolino Ruperto², Anasuya Hazra³, Ronnie Wang⁴, Charles Mebus⁴, Christine Alvey⁴, Manisha Lamba⁴, Sriram Krishnaswami⁴, Thomas C Stock³, Umberto Conte⁵, Min Wang⁵, Nikolay Tzaribachev⁶, Ivan Foeldvari⁷, Gerd Horneff⁸, Daniel Kingsbury⁹, Elena Koskova¹⁰, Elzbieta Smolewska¹¹, Richard K Vehe¹², Zbigniew Zuber¹³, Daniel J Lovell¹ and Alberto Martini², ¹Pediatric Rheumatology Collaborative Study Group, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, ²Istituto Giannina Gaslini, Genoa, Italy, ³Pfizer Inc, Collegeville, PA, ⁴Pfizer Inc, Groton, CT, ⁵Pfizer Inc, New York, NY, ⁶Pediatric Rheumatology Research Institute, Bad Bramstedt, Bad Bramstedt, Germany, ⁷Hamburger Zentrum für Kinder- und Jugendrheumatologie, Hamburg, Germany, ⁸Asklepios Klinik, Sankt Augustin, Germany, ⁹Randall Children's Hospital, Portland, OR, ¹⁰National Institute of Rheumatic Diseases, Piestany, Piestany, Slovakia, ¹¹Department of Pediatric Cardiology and Rheumatology, Medical University of Lodz, Lodz, Poland, ¹²University of Minnesota Masonic Children’s Hospital, Minneapolis, MN, ¹³St Louis Children’s Hospital ODS Rheumatology and Neurology, Krakow, Poland
Background/Purpose: Tofacitinib is an oral Janus kinase inhibitor that is being investigated for juvenile idiopathic arthritis (JIA). Here, we report the pharmacokinetics (PK), safety, and…
Abstract Number: 389 • 2016 ACR/ARHP Annual Meeting
Long-Term Effectiveness and Safety of Abatacept in Juvenile Idiopathic Arthritis: Interim Results from the Abatacept in JIA Registry
DJ Lovell¹, N Ruperto², N Tzaribachev³, A Zeft⁴, R Cimaz⁵, V Stanevica⁶, G Horneff⁷, J Bohnsack⁸, TA Griffin⁹, R Carrasco¹⁰, M Trachana¹¹, JA Dare¹², I Foeldvari¹³, RK Vehe¹⁴, TA Simon¹⁵, N Baker¹⁵, Hermine I. Brunner¹⁶ and A Martini², ¹Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ²Istituto G. Gaslini Pediatria II Reumatologia, Genova, Italy, ³University Medical Center Schleswig-Holstein, Bad Bramstedt, Germany, ⁴Pediatric Rheumatology, Cleveland Clinic, Cleveland, OH, ⁵Pediatrics, Ospedale Pediatrico Anna Meyer, Florence, Italy, ⁶Riga Stradins University, Riga, Latvia, ⁷Asklepios Klinik Zentrum für Allgemeine Paediatrie und Neonatologie, Sankt Augustin, Germany, ⁸University of Utah School of Medicine, Salt Lake City, UT, ⁹Levine Children’s Hospital at Carolinas Medical Center, Charlotte, NC, ¹⁰Pediatric Rheumatology, Specially For Children, Austin, TX, ¹¹Hippokration General Hospital, Thessaloniki, Greece, ¹²University of Arkansas Medical Center, Little Rock, AR, ¹³Hamburg Centre for Pediatric Rheumatology, Hamburg, Germany, ¹⁴University of Minnesota, Minneapolis, MN, ¹⁵Bristol-Myers Squibb, Princeton, NJ, ¹⁶Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH
Background/Purpose: Abatacept is a widely approved and used biologic in children with juvenile idiopathic arthritis (JIA). The purpose of this study was to describe the…
Abstract Number: 390 • 2016 ACR/ARHP Annual Meeting
Use, Safety and Efficacy of Zrc 3197, a Biosimilar Candidate for Reference Adalimumab (Humira) from a Tertiary Pediatric Rheumatology Centre in India
Manjari Agarwal¹, Abhay Shivpuri², Sumidha Mittal³, Amit Khosla⁴ and Sujata Sawhney⁵, ¹Institute of Child Health, Attending Consultant, New Delhi, India, ²Division of Pediatric Rheumatology,Institute of Child Health, Post Doctoral Fellow, New Delhi, India, ³Post Doctoral Fellow, New Delhi, India, ⁴Department of Ophthalmology,Sir Ganga Ram Hospital, Senior Consultant, New Delhi, India, ⁵Paediatric rheumatology, Senior Consultant, New Delhi, India
Background/Purpose: Reference Adalimumab is not available in our country but biosimilar ZRC 3197 is(1). This is lower priced and as healthcare is primarily self funded…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].